ArticleDiagnostic pathology2013
Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Article in Diagnostic pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.Journal of cellular biochemistry · 2018Pooled it
- Prognostic Role of MicroRNA-126 for Survival in Malignant Tumors: A Systematic Review and Meta-Analysis.Disease markers · 2015Pooled it
- Evaluation of Exosome-Based Delivery of Tumor-Suppressive microRNAs for Novel Therapy in Peritoneal Dissemination of Gastric Cancer: Evidence from Experimental Animal Models.Annals of surgical oncology · 2025Article
- miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.Cancers · 2024Article
- Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy.Oncology letters · 2018Article
- Ultrasound‑targeted microbubble destruction‑mediated miR‑205 enhances cisplatin cytotoxicity in prostate cancer cells.Molecular medicine reports · 2018Article
- MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9.Oncology letters · 2018Article
- The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.PloS one · 2018Article
- Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?International journal of molecular sciences · 2017Review
- Targeting MicroRNAs in Prostate Cancer Radiotherapy.Theranostics · 2017Review
- Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder.Cancer medicine · 2016Article
- Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.Cellular and molecular life sciences : CMLS · 2016Review
- MicroRNA-126 inhibits tumor cell invasion and metastasis by downregulating ROCK1 in renal cell carcinoma.Molecular medicine reports · 2016Article
- MicroRNA‑126 inhibits proliferation and metastasis by targeting pik3r2 in prostate cancer.Molecular medicine reports · 2016Article
- High microRNA-23a expression in laryngeal squamous cell carcinoma is associated with poor patient prognosis.Diagnostic pathology · 2015Article
- Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Dysregulation of cell cycle related genes and microRNAs distinguish the low- from high-risk of prostate cancer.Diagnostic pathology · 2014Article
- Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer.Diagnostic pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNumerous studies have suggested that microRNA-126 (miR-126) is involved in development of various cancer types as well as in malignant proliferation and invasion. However, its role in human prostate cancer (PCa) is still unclear. The aim of this study was to investigate miR-126 expression in PCa and its prognostic value for PCa patients undergoing radical prostatectomy.
methodsA series of 128 cases with PCa were evaluated for the expression levels of miR-126 by quantitative reverse-transcription PCR (qRT-PCR). Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between miR-126 expression and prognosis of PCa patients.
resultsCompared with non-cancerous prostate tissues, the expression level of miR-126 was significantly decreased in PCa tissues (PCa vs. non-cancerous prostate: 1.05 ± 0.63 vs. 2.92 ± 0.98, P < 0.001). Additionally, the loss of miR-126 expression was dramatically associated with aggressive clinical pathological features, including advanced pathological stage (P = 0.001), positive lymph node metastasis (P = 0.006), high preoperative PSA (P = 0.003) and positive angiolymphatic invasion (P = 0.001). Moreover, Kaplan-Meier survival analysis showed that PCa patients with low miR-126 expression have shorter biochemical recurrence (BCR)-free survival than those with high miR-126 expression. Furthermore, multivariate analysis indicated that miR-126 expression was an independent prognostic factor for BCR-free survival after radical prostatectomy.
conclusionThese findings suggest for the first time that the loss of miR-126 expression may play a positive role in the malignant progression of PCa. More importantly, the downregulation of miR-126 may serve as an independent predictor of BCR-free survival in patients with PCa. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1740080792113255.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.